{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:15:04Z","timestamp":1773195304753,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Differentiated thyroid carcinoma (DTC) is common, and its rate is on the rise globally. Radioactive iodine, RAI (I-131), is widely used as an adjuvant therapy or for remnant ablation. There is growing awareness about the effects of RAI (I-131) on ovarian reserve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This meta-analysis aimed to evaluate whether RAI therapy impairs ovarian reserve as assessed by anti-M\u00fcllerian hormone (AMH) and follicle-stimulating hormone (FSH) levels. A systematic literature search was conducted in PubMed, MEDLINE, Google Scholar, and EBSCO for relevant articles published in the English language. The literature search was conducted during October and November 2024, and the studies were included if they were published in the period from 2015 to 2024. The keywords used were ovarian reserve, ovarian function, female fertility, radioactive iodine, RAI (I-131), follicle-stimulating hormone (FSH), and anti-M\u00fcllerian hormone (AMH). MeSH terms used: Iodine Radioisotopes, Ovarian Reserve, and Thyroid Neoplasms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      Out of the two hundred and sixty-nine studies retrieved, 160 remained after duplication removal, of which 17 full texts were screened. However, only six studies (with 430 patients) were included in the final meta-analysis. AMH level were significantly lower after RAI (I-131) with a mean difference (MD) of 1.96. 95%\n                      <jats:italic>CI<\/jats:italic>\n                      , 0.53 to3.40. The levels were higher in the RAI (I-131) group after removing studies with significant heterogeneity, MD, 0.36. 95%\n                      <jats:italic>CI<\/jats:italic>\n                      , 0.17 to 0.55. FSH levels were significantly higher following RAI (I-131), MD -1.07, 95%\n                      <jats:italic>CI<\/jats:italic>\n                      , -2.02 to-0.13.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence shows a significant reduction in anti-M\u00fcllerian hormone (AMH), and significant increase in FSH levels after RAI (I-131), but data are heterogeneous. Larger prospective studies with standardized outcome measures are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1636824","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:32:13Z","timestamp":1773120733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Radioactive iodine effects on ovarian reserve: a systematic review and metaanalysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Salwa Q.","family":"Bukhari","sequence":"first","affiliation":[{"name":"University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyder","family":"Mirghani","sequence":"additional","affiliation":[{"name":"University of Tabuk","place":["Tabuk, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/0118744710249684231013072013","article-title":"Radioactive iodine in differentiated carcinoma of thyroid: an overview","volume":"17","author":"Singh","year":"2024","journal-title":"Curr Radiopharm"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2024.05.002","article-title":"Radioactive iodine therapy in differentiated thyroid cancer: an update on dose recommendations and risk of secondary primary Malignancies","volume":"54","author":"Nguyen","year":"2024","journal-title":"Semin Nucl Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0597","article-title":"Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: A joint statement from the American thyroid association, the European association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European thyroid association","volume":"29","author":"Tuttle","year":"2019","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.19.22626","article-title":"Radioactive iodine therapy in differentiated thyroid cancer: 2020 update","volume":"215","author":"Ciarallo","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00423-024-03316-w","article-title":"Oncologic outcomes and surgical completeness of remote-access thyroidectomy: a systematic review and network meta-analysis","volume":"409","author":"Nguyen","year":"2024","journal-title":"Langenbecks Arch Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/hed.27644","article-title":"Comparison of surgical outcomes of transoral robotic and endoscopic thyroidectomy: A systematic review and network meta-analysis","volume":"46","author":"Nguyen","year":"2024","journal-title":"Head Neck"},{"key":"B7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-2505-7_16","article-title":"Radioactive iodine for papillary thyroid carcinoma","volume":"2534","author":"Chan","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2021.0288","article-title":"Radioiodine remnant ablation for differentiated thyroid cancer: A systematic review and meta-analysis","volume":"147","author":"James","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1038\/s41598-022-07592-8","article-title":"Radioactive iodine and female fertility","volume":"12","author":"Navarro","year":"2022","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0356","article-title":"The effect of radioactive iodine therapy on ovarian function and fertility in female thyroid cancer patients: A systematic review and meta-analysis","volume":"31","author":"Piek","year":"2021","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2021.04.002","article-title":"Decline in anti-M\u00fcllerian hormone concentrations following radioactive iodine treatment in women with differentiated thyroid cancer: A systematic review and meta-analysis","volume":"148","author":"Anagnostis","year":"2021","journal-title":"Maturitas"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac039","article-title":"Evaluation of female fertility-AMH and ovarian reserve testing","volume":"107","author":"Cedars","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13048-025-01732-0","article-title":"Assessment and\u00a0prediction models for the quantitative and qualitative reserve of the ovary using\u00a0machine learning","volume":"18","author":"Koike","year":"2025","journal-title":"J Ovarian Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-024-07741-6","article-title":"Ovarian reserve does not influence natural conception: insights from infertile women","volume":"310","author":"Galati","year":"2024","journal-title":"Arch Gyn Obstet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60091387","article-title":"Anti-m\u00fcllerian hormone level determinants among non-polycystic-ovary-syndrome women undergoing in vitro fertilization: A retrospective cross-sectional study","volume":"60","author":"Kolcsar","year":"2024","journal-title":"Med Kun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5653\/cerm.2019.46.2.50","article-title":"Clinical application of serum anti-M\u00fcllerian hormone in women","volume":"46","author":"Oh","year":"2019","journal-title":"Clin Exp Reprod Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/molehr\/gat024","article-title":"Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection","volume":"19","author":"Jeppesen","year":"2013","journal-title":"Mol Hum Reprod"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa513","article-title":"Anti-m\u00fcllerian hormone and ovarian reserve: update on assessing ovarian function","volume":"105","author":"Moolhuijsen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.591764","article-title":"Editorial: ovarian ageing: pathophysiology and recent development of maintaining ovarian reserve","volume":"11","author":"Kawamara","year":"2020","journal-title":"Front Endocrinol Lausanne"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.14588","article-title":"Association between biomarkers of ovarian reserve and infertility among older women of reproductive age","volume":"318","author":"Steiner","year":"2017","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0187","article-title":"Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine","volume":"10","author":"Adamska","year":"2021","journal-title":"Endocr Conn"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0129","article-title":"Effects of radioactive iodine therapy on ovarian reserve: A prospective pilot study","volume":"28","author":"Evranos","year":"2018","journal-title":"Thyroid"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1510-3","article-title":"Anti-M\u00fcllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer","volume":"60","author":"Giusti","year":"2018","journal-title":"Endocrine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s43043-023-00147-5","article-title":"The effect of radioactive iodine therapy on anti-M\u00fcllerian hormone changes in women with thyroid cancer at reproductive age: a prospective study","volume":"28","author":"Hosseini","year":"2023","journal-title":"Mid East Fertil Soc J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-020-0075-z","article-title":"Cross-sectional and prospective study on anti-M\u00fcllerian hormone changes in a cohort of pre-menopausal women with a history of differentiated thyroid cancer","volume":"13","author":"Mittica","year":"2020","journal-title":"Thyroid Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0442","article-title":"A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: results of a prospective pilot study","volume":"28","author":"Yaish","year":"2018","journal-title":"Thyroid"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0343","article-title":"Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer","volume":"25","author":"Wu","year":"2015","journal-title":"Thyroid"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e12937","DOI":"10.7759\/cureus.12937","article-title":"The optimal activity of radioactive iodine for remnant ablation in low\/intermediate risk differentiated thyroid carcinoma: A continuous controversy and meta-analysis","volume":"13","author":"Mirghani","year":"2021","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673331849240930140120","article-title":"A promising druggable target for translational therapy of ovarian cancer: A molecular profiling of therapeutic innovations, extracellular vesicle acquired resistance, and signaling pathways","author":"Mustafa","year":"2025","journal-title":"Curr Med Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4103\/apjon.apjon_23_17","article-title":"Seeking optimal management for radioactive iodine therapy-induced adverse effects","volume":"4","author":"Charalambous","year":"2017","journal-title":"Asia Pac J Oncol Nurs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7719","article-title":"131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study","volume":"86","author":"Ceccarelli","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-115639","article-title":"Evaluation of ovarian reserve with AMH level in patients with well-differentiated thyroid cancer receiving radioactive iodine ablation treatment","volume":"124","author":"Ac\u0131bucu","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0504","article-title":"Longitudinal analysis of the effect of radioiodine therapy on ovarian reserve in females with differentiated thyroid cancer","volume":"30","author":"van Velsen","year":"2020","journal-title":"Thyroid"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-69-1-186","article-title":"Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine","volume":"69","author":"Raymond","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.05.034","article-title":"Fertility\u00a0preservation and reproduction in patients facing gonadotoxic therapies: an\u00a0Ethics Committee opinion","volume":"110","year":"2018","journal-title":"Fertil Steril"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-837666","article-title":"Ovarian function after radioiodine therapy in patients with thyroid cancer","volume":"113","author":"Souza Ros\u00e1rio","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.02.027","article-title":"Ovarian reserve testing: a user\u2019s guide","volume":"217","author":"Tal","year":"2017","journal-title":"Am J Obstet Gyn"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0884-2","article-title":"Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies","volume":"41","author":"Pacini","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.09.001","article-title":"Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review","volume":"41","author":"Clement","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000468927","article-title":"Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: literature review of utility, dose, and toxicity","volume":"6","author":"Andresen","year":"2017","journal-title":"Eur Thyroid J"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1636824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:32:14Z","timestamp":1773120734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1636824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":44,"alternative-id":["10.3389\/fendo.2026.1636824"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1636824","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1636824"}}